Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3978/j.issn.2223-4683.2015.06.04 http://scihub22266oqcxt.onion/10.3978/j.issn.2223-4683.2015.06.04 C4520710!4520710!26236649     free     free     free       Transl+Androl+Urol 2015 ; 4 (3): 294-300 Nephropedia Template TP {{tp|p=26236649|t=2015. Outlining the limits of partial nephrectomy |pdf=|usr=}}{{26236649}} gab.com Text Outlining the limits of partial nephrectomy JO: Transl Androl Urol http://www.kidney.de/pget.php?&tw=1&pmid=26236649 #FOAvip Amongst nephron-sparing modalities, partial nephrectomy (PN) is the standard of care in the treatment of renal cell carcinoma (RCC). Despite the increasing utilization of PN, particularly propagated by robot-assisted, minimally invasive approaches for small renal masses (SRMs), the limits of PN appear to be also evolving. In this review, we sought to address the tumour stage beyond which PN may be oncologically perilous. While the evidence supports PN in the treatment of tumours < pT2a, PN may have a role in advanced or metastatic RCC. Other scenarios wherein PN has limited utility are also explored, including anatomical or surgical factors that dictate the difficulty of the case, such as prior renal surgery. Lastly, we discuss the emerging role of molecular biomarkers, specifically epigenetics, to aid in the risk stratification of SRMs and to select tumours optimally suited for PN. Twit Text FOAVip Outlining the limits of partial nephrectomy ????Transl Androl Urol http://www.kidney.de/pget.php?&tw=1&pmid=26236649 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26236649 #FOAvip English Wikipedia <ref>{{Cite pmid|26236649}}</ref> Outlining the limits of partial nephrectomy #MMPMID26236649 Chopra S; Satkunasivam R; Kundavaram C; Liang G; Gill IS Transl Androl Urol 2015[Jun]; 4 (3): 294-300 PMID26236649show ga Amongst nephron-sparing modalities, partial nephrectomy (PN) is the standard of care in the treatment of renal cell carcinoma (RCC). Despite the increasing utilization of PN, particularly propagated by robot-assisted, minimally invasive approaches for small renal masses (SRMs), the limits of PN appear to be also evolving. In this review, we sought to address the tumour stage beyond which PN may be oncologically perilous. While the evidence supports PN in the treatment of tumours < pT2a, PN may have a role in advanced or metastatic RCC. Other scenarios wherein PN has limited utility are also explored, including anatomical or surgical factors that dictate the difficulty of the case, such as prior renal surgery. Lastly, we discuss the emerging role of molecular biomarkers, specifically epigenetics, to aid in the risk stratification of SRMs and to select tumours optimally suited for PN. äOutlining the limits of partial nephrectomy (epmc).pdf DeepDyve Pubget Overpricing